

PATENT
030639.0034.CPA1In the Claims

Please amend claims 38 and 40-47 as follows.

E5 1 38. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered subcutaneously.

E5 3 39. (Amended) A method according to claim 38 wherein said insulin and said glucagon-like peptide 1 (7-36) amide analogue are administered to the human at a selected time prior to ingestion of a meal.

E6 4 40. (Amended) A method according to any of claims 38-40 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36).

E7 F 5 41. (Amended) A method according to any of claims 38-41 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

E7 6 42. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered subcutaneously.

E8 7 43. (Amended) A method according to claim 42 wherein said mammal is a human.

E9 8 44. (Amended) A method according to claim 43 wherein said glucagon-like peptide 1 (7-36) amide analogue is administered to the human at a selected time prior to ingestion of a meal.

E10 9 45. (Amended) A method according to any of claims 43-45 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

PATENT
030639.0034.CPA1

11 10 47. (Amended) A method according to any of claims 43-45 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36). 6-8

Please add the following new claims 48-52.

11 11-48. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering subcutaneously to the mammal an effective amount of a peptide selected from the group consisting of

- (a) glucagon-like peptide 1 (7-37);
- (b) glucagon-like peptide 1 (7-36) amide; and
- (c) an effective fragment or analogue of (a) or (b).

12 11 49. (New) The method of claim 48 further comprising administering an insulin.

13 50. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering subcutaneously to the mammal an effective amount of a glucagon-like peptide 1-related peptide.

14 13 51. (New) The method of claim 50 further comprising administering an insulin.

15 16 11 13 52. (New) The method according to any of claims 38, 43, 48 and 50 wherein the insulin-requiring diabetes is Type I diabetes.--

REMARKS

Claims 38-52 are pending in the instant application. Claims 48-52 have been added, and find full support in the specification, as do the amendments to the existing claims. For example, amendments to all claims are supported on page 2, lines 1-12.